Alaggio R, Coffin CM, Weiss SW et al (2009) Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol 33:645–658. https://doi.org/10.1097/PAS.0b013e3181963c9c

Article  PubMed  Google Scholar 

Anderson WJ, Jo VY (2019) Pleomorphic liposarcoma: updates and current differential diagnosis. Semin Diagn Pathol 36:122–128. https://doi.org/10.1053/j.semdp.2019.02.007

Article  PubMed  Google Scholar 

Araujo DM, Druta M, Agulnik M, et al. (2020) SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma". J Clin Oncol 38. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS11569

Assi T, Kattan J, Rassy E et al (2020) Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Crit Rev Oncol/Hematol 153:103029. https://doi.org/10.1016/j.critrevonc.2020.103029

Article  PubMed  Google Scholar 

Barretina J, Taylor BS, Banerji S et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715–721. https://doi.org/10.1038/ng.619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauer TM, Gounder MM, Weise AM et al (2018) A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36:11514. https://doi.org/10.1200/JCO.2018.36.15_suppl.11514

Article  Google Scholar 

Beird HC, Wu C-C, Ingram DR et al (2018) Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Mol Case Stud 4:a002386. https://doi.org/10.1101/mcs.a002386

Article  CAS  Google Scholar 

Boland JM, Colby TV, Folpe AL (2012) Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features. Am J Surg Pathol 36:1395–1403. https://doi.org/10.1097/PAS.0b013e3182562bc1

Article  PubMed  Google Scholar 

Chamberlain F, Benson C, Thway K et al (2021) Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol 17:2659–2670. https://doi.org/10.2217/fon-2020-1092

Article  CAS  PubMed  Google Scholar 

Cheng H, Dodge J, Mehl E et al (2009) Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol 40:1244–1251. https://doi.org/10.1016/j.humpath.2009.01.011

Article  CAS  PubMed  Google Scholar 

Chowdhry V, Goldberg S, DeLaney TF et al (2018) Myxoid liposarcoma: treatment outcomes from chemotherapy and radiation therapy. Sarcoma 2018:8029157. https://doi.org/10.1155/2018/8029157

Article  PubMed  PubMed Central  Google Scholar 

Coindre J-M, Pédeutour F, Aurias A (2010) Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 456:167–179. https://doi.org/10.1007/s00428-009-0815-x

Article  CAS  PubMed  Google Scholar 

Conyers R, Young S, Thomas DM (2010) Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011:483154. https://doi.org/10.1155/2011/483154

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crozat A, Åman P, Mandahl N et al (1993) Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363:640–644. https://doi.org/10.1038/363640a0

Article  CAS  PubMed  Google Scholar 

Davidović R, Sopta J, Mandušić V et al (2013) p14 ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. Med Oncol 30:1–8. https://doi.org/10.1007/s12032-013-0682-9

Article  CAS  Google Scholar 

de Jonge M, de Weger VA, Dickson MA et al (2017) A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer 76:144–151. https://doi.org/10.1016/j.ejca.2017.02.005

Article  CAS  PubMed  Google Scholar 

De Vita A, Mercatali L, Recine F et al (2016) Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther 9:6233–6246. https://doi.org/10.2147/OTT.S112580

Article  PubMed  PubMed Central  Google Scholar 

Dei Tos AP (2000) Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol 4:252–266. https://doi.org/10.1053/adpa.2000.8133

Article  CAS  PubMed  Google Scholar 

Demetri GD, Fletcher CD, Mueller E et al (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96:3951–3956. https://doi.org/10.1073/pnas.96.7.3951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demetri GD, Von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793. https://doi.org/10.1200/JCO.2015.62.4734

Article  CAS  PubMed  Google Scholar 

Demicco EG (2019) Molecular updates in adipocytic neoplasms. Semin Diagn Pathol 36:85–94. https://doi.org/10.1053/j.semdp.2019.02.003

Article  PubMed  Google Scholar 

Demicco EG, Torres KE, Ghadimi MP et al (2012) Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 25:212–221. https://doi.org/10.1038/modpathol.2011.148

Article  CAS  PubMed  Google Scholar 

Dickson MA, Tap WD, Keohan ML et al (2013) Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31:2024–2028. https://doi.org/10.1200/JCO.2012.46.5476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2:937–940. https://doi.org/10.1001/jamaoncol.2016.0264

Article  PubMed  PubMed Central  Google Scholar 

Dickson MA, Koff A, D’Angelo SP et al (2019) Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 37:11004–11004. https://doi.org/10.1200/JCO.2019.37.15_suppl.11004

Article  Google Scholar 

Enzinger FM, Winslow DJ (1962) Liposarcoma: a study of 103 cases. Virchows Arch Pathol Anat Physiol Klin Med 335:367–388. https://doi.org/10.1007/BF00957030

Article  CAS  PubMed  Google Scholar 

Evans HL (1979) Liposarcoma a study of 55 cases with a reassessment of its classification. Am J Surg Pathol 3:507–524. https://doi.org/10.1097/00000478-197912000-00004

Article  CAS  PubMed  Google Scholar 

Fiore M, Grosso F, Lo Vullo S et al (2007) Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 109:2522–2531. https://doi.org/10.1002/cncr.22720

Article  PubMed  Google Scholar 

Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO classification of tumours of soft tissue and bone.IARC,France

Forni C, Minuzzo M, Virdis E et al (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8:449–457. https://doi.org/10.1158/1535-7163.MCT-08-0848

Article  CAS  PubMed  Google Scholar 

Funahashi Y, Okamoto K, Adachi Y et al (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334–1342. https://doi.org/10.1111/cas.12488

Article